Amneal Pharmaceuticals LLC.

Products

Category

Product

Brand

Description

Biosimilars (BIO090E)

Alymsys (bevacizumab)		It is a biosimilar to Avastins, Alymsys targets angiogenesis, effectively inhibiting blood vessel growth in tumors. Approved for various cancers, including colorectal, lung, and renal, it provides an affordable option for oncologists and patients.
Releuko (filgrastim)		Releuko is a biosimilar to Neupogen; Releuko helps manage neutropenia by stimulating white blood cell production, which is particularly beneficial for cancer patients undergoing chemotherapy. It provides comparable efficacy and safety at a lower cost.
Flynetra™ (pegfilgrastim)		A biosimilar to Neulasta, Flynetra™, aids in reducing infection risk by supporting neutrophil recovery post-chemotherapy. This pegylated formulation offers longer-lasting effects, requiring fewer doses and supporting patient convenience.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment